llms.txt
Compare with other sites' llms.txt files →# Affinix
> Simulate drug interactions, organ failure and therapeutic windows in real time. Built for pharmacy and medical students, clinicians and researchers.
All numeric values are deterministic model output for research and teaching, not clinical dosing guidance.
## Overview
Affinix is an interactive clinical pharmacology and pharmacometrics platform designed for clinicians, clinical researchers, pharmacologists, and educators. It simulates the concentration-time profiles and target receptor engagement of multi-drug regimens across patient-specific physiology, kidney and liver function, pregnancy, critical care, and pharmacogenomics.
## Core capabilities
### Multi-compartment pharmacokinetic modeling
- **Concentration-time trajectories:** Multi-compartmental plasma and effect-site concentration profiles for parent compounds and active metabolites across single doses, loading doses, and chronic steady-state regimens.
- **Formulation kinetics:** Immediate release, extended release, enteric-delayed release, intravenous bolus, continuous infusion, long-acting depot formulations, and rectal delivery (cannula solutions, suppositories, and retention enemas with dual hemorrhoidal venous drainage).
- **Therapeutic reference windows:** Direct visualization of plasma exposure against minimum effective concentrations, therapeutic ranges, and toxicity ceilings.
### Dynamic physiological and environmental clearance modulation
- **Renal function and active transport:** Continuous scaling of renal filtration and tubular secretion across KDIGO eGFR stages (from normal filtration and augmented renal clearance down to severe impairment and dialysis) alongside renal transporter interactions (OCT2, OAT1, OAT3, MATE1, MATE2-K, P-gp, BCRP).
- **Urinary pH ion trapping:** Ionization-dependent tubular reabsorption and renal elimination shifts across acidic and alkaline urinary pH gradients.
- **Hepatic function and portosystemic shunting:** Fractional hepatic clearance and first-pass bioavailability adjustments across Child-Pugh classes A, B, and C, including prodrug bioactivation attenuation in cirrhosis.
- **Plasma protein binding:** Free-fraction shifts and competitive displacement across serum albumin and alpha-1-acid glycoprotein gradients.
- **Gastrointestinal physiology:** Absorption and transit modulation across gastroparesis, inflammatory bowel disease, celiac disease, bariatric surgery, and gastric acid suppression.
- **Pharmacogenomics and metabolic interactions:** Competitive inhibition, mechanism-based enzyme inactivation, and transcriptional induction across Cytochrome P450 (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4), UGT (UGT1A1, UGT1A4, UGT1A9, UGT2B7), and Phase II pathways (TPMT, DPYD, NAT2), integrated with CPIC metabolizer phenotypes.
- **Thermal burn injury and critical care resuscitation:** Fluid-shift volume expansion, hypoalbuminemia, augmented renal clearance, and acute-phase protein remodeling across resuscitation phases.
- **Pregnancy and lactation:** Trimester-specific volume expansion, glomerular hyperfiltration, gestational enzyme induction, placental transfer, and breast milk exposure modeling.
- **Onco-geriatric sarcopenia and cachexia:** Body-composition distribution shifts and cystatin C vs creatinine renal function reconciliation in low muscle mass.
- **Erythrocyte enzymopathies and hemoglobinopathies:** G6PD deficiency oxidative hemolysis risk stratification and sickle cell hyperdynamic clearance remodeling.
- **Biotherapies and radiopharmaceuticals:** Target-mediated drug disposition (TMDD) and FcRn salvage recycling for monoclonal antibodies, plus organ dosimetry and kidney protection modeling for targeted radionuclide therapies.
### Pharmacodynamics and biological pathways
- **Receptor occupancy:** Competitive target binding at active biophase effect sites across ten biological systems:
1. *GABAergic signaling:* GABAA, GABAB, Alpha2Delta.
2. *Serotonergic signaling:* SERT, 5HT1A, 5HT2A, 5HT2C, 5HT1B, 5HT1D.
3. *Dopaminergic signaling:* DAT, D2, VMAT2.
4. *Noradrenergic signaling:* NET, Alpha1, Alpha2, Beta1, Beta2.
5. *Glutamatergic signaling:* NMDA, AMPA.
6. *Opioidergic and histaminergic signaling:* MOR, KOR, DOR, H1, M1.
7. *Endocannabinoid signaling:* CB1, CB2.
8. *Cardiovascular and hemodynamic signaling:* Beta1, Alpha1, AT1, ACE, CACNA1C, NKCC2, NCCT, MR, PDE5, NaK_ATPase.
9. *Hemostatic and coagulation cascade:* P2Y12, COX1, COX2, FXa, Factor_IIa, VKORC1.
10. *Metabolic and endocrine signaling:* GLP1R, SGLT2, HMGCR, AMPK, GR, PR, EPOR, G-CSFR, PCSK9, TACR1.
## Supported therapeutic classes
Affinix includes **1.1K+ validated clinical drugs and therapeutic biotherapeutics** across 15 physiological subsystems and major clinical specialties:
- Antidepressants, antipsychotics, mood stabilizers, anxiolytics, and anticonvulsants
- Analgesics, opioids, anesthetics, and neuromuscular blockers
- Cardiovascular, antihypertensive, antiarrhythmic, and anticoagulant agents
- Anti-infectives, antibacterials, azole antifungals, and direct-acting antivirals
- Oncology small molecules, targeted kinase inhibitors, and supportive care
- Monoclonal antibodies, immunomodulators, and targeted radiopharmaceuticals
- Endocrine, metabolic, gastrointestinal, and critical care therapies
## When to use this platform
Researchers, educators, and clinical learners can use Affinix to explore:
1. Multi-drug interactions: comparing baseline vs co-prescribed exposure when combining enzyme inhibitors, inducers, and narrow-therapeutic-index substrates.
2. Organ impairment dosing: visualizing accumulation and half-life extension across renal and hepatic impairment stages.
3. Receptor occupancy vs safety thresholds: relating unbound plasma concentrations to target engagement and dose-limiting toxicities.
4. Special populations: inspecting pharmacokinetic shifts in pregnancy, critical care burns, sarcopenia, G6PD deficiency, and sickle cell disease.
Do not use Affinix for individual patient diagnosis, treatment selection, or clinical prescribing decisions.
## Platform access
- **Landing page and overview:** [https://affinix.bio](https://affinix.bio)
- **Interactive simulator workspace:** [https://affinix.bio/app](https://affinix.bio/app)
- **Legal and terms of use:** [https://affinix.bio/legal](https://affinix.bio/legal)
- **Developer:** [Charles Duprat](https://dupr.at)